Paul J Kenny, PhD
img_Paul J Kenny
PROFESSOR & CHAIR | Neuroscience
Research Topics
Addiction, Behavior, Brain, Drug Design and Discovery, Epigenetics, Gene Expressions, Molecular Biology, Neurobiology, Neuroscience, Obesity, Schizophrenia
Multi-Disciplinary Training Area
Disease Mechanisms and Therapeutics (DMT), Genetics and Genomic Sciences [GGS]
The Kenny Laboratory is focused on understanding the neurobiological mechanisms of drug addiction, obesity and schizophrenia, with an emphasis on the role of nicotinic acetylcholine receptors (nAChRs) in these processes. They employ a multidisciplinary approach that includes complex behavioral paradigms, physiological analyses and molecular biological techniques. Current projects include the utilization of vector-based delivery systems to modify gene expression in the brains of rodents to identify novel signaling cascades that may play a role in addiction-like behaviors. Search PubMed for articles

BA, Trinity College Dublin

PhD, University of London


Annual Alton Ochsner Award Relating Smoking and Disease

Ochsner Health


Daniel H. Efron Research Award

American College of Neuropsychopharmacology (ACNP)


Tom Connor Distinguished Investigator Award

Neuroscience Ireland


Mathilde Solowey Lecture Award in the Neurosciences

Foundation for Advanced Education in the Sciences


Jacob P. Waletzky Memorial Award

Society for Neuroscience

FBI Cyber Series - Nicotine Addiction: Unexpected Cells, Circuits, and Sicknesses by Paul Kenny, PhD
Paul Kenny, PhD, Director, Drug Discovery Institute

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Kenny during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.


  • AstraZeneca
  • EpiVario

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Eolas Therapeutics, Inc.

Royalty Payments:

  • Eolas Therapeutics, Inc.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.